Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

115.87 +0.44 (+0.38%)
Official Closing Price Updated: 7:00 PM EDT, Mar 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,952,160
Open 115.78
Bid (Size) 115.50 (600)
Ask (Size) 116.80 (100)
Prev. Close 115.43
Today's Range 114.38 - 116.80
52wk Range 73.31 - 125.14
Shares Outstanding 2,531,374,696
Dividend Yield 2.93%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Grand Divergence: Finance Surges as Health Care Braces for a Historic Q1 Earnings Slump
As the first quarter of 2026 draws to a close, the S&P 500 is witnessing one of the most dramatic sector performance splits in recent financial history. According to consensus estimates as of March 17,... 
Via MarketMinute
Topics Earnings Economy Initial Public Offering
News headline image
Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
From Merck Sharp & Dohme
Via Business Wire

Performance

YTD
+8.8%
+8.8%
1 Month
-4.7%
-4.7%
3 Month
+17.9%
+17.9%
6 Month
+42.9%
+42.9%
1 Year
+22.2%
+22.2%

More News

Read More
News headline image
The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery
Via MarketMinute
Topics Artificial Intelligence Initial Public Offering Stocks
Merck & Co. Inc. (NYSE:MRK) Offers a Steady Dividend Backed by Strong Fundamentals ↗
Via Chartmill
News headline image
Merck & Co. Trades Ex-Dividend as Healthcare Emerges as a Volatility Hedge in 2026
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research
From Merck & Co., Inc.
Via Business Wire
News headline image
1 ETF That Could Turn $100 Per Month Into $67,380 ↗
Via The Motley Fool
Topics ETFs Economy World Trade
News headline image
Flight to Quality: JPMorgan and Eli Lilly Emerge as Defensive Anchors Amid Geopolitical Storm
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
The Dividend Shield: How Meta, Microsoft, Merck, and Target are Signal-Boosting Balance Sheet Strength in a Cooling 2026 Economy
Via MarketMinute
Topics Artificial Intelligence Economy Workforce
News headline image
1 Unpopular Stock That Deserves Some Love and 2 We Avoid
Via StockStory
News headline image
BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
Via MarketMinute
News headline image
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
Via Finterra
Topics Economy Intellectual Property Lawsuit
News headline image
2 Dow Jones Stocks to Research Further and 1 Facing Headwinds
Via StockStory
Topics Stocks
News headline image
1 Dividend Stock to Buy Hand Over Fist and 1 to Avoid ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Undervalued Names Too Cheap to Ignore ↗
Via MarketBeat
News headline image
The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies ↗
Via The Motley Fool
News headline image
Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era
Via Finterra
Topics Intellectual Property
News headline image
ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth
Via MarketMinute
Topics Earnings Economy
News headline image
2 High-Flying Stocks With More Upside to Buy and Hold ↗
Via The Motley Fool
Topics Artificial Intelligence Supply Chain
News headline image
IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions ↗
Via Stocktwits
Topics Earnings Supply Chain
News headline image
IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
USDA Deploys $100 Million 'Screwworm Challenge' to Safeguard U.S. Livestock and Dairy Frontier
Via MarketMinute
Topics Economy
News headline image
IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
From Merck & Co., Inc
Via Business Wire

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 115.87
When was Merck & Co last traded?
The last trade of Merck & Co was at 03/17/26 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 293.31B
How many shares of Merck & Co are outstanding?
Merck & Co has 293B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.